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Abstract
Background: Antrodia cinnamomea (AC) is a popular medicinal mushroom in Taiwan that has been widely used
for treatment of various cancers. Few clinical studies have reported its application and efficiency in therapeutic
chemotherapy strategies. We performed a double-blind, randomized clinical study to investigate whether AC given
for 30 days had acceptable safety and efficacy in advanced cancer patients receiving chemotherapy.
Methods: Patients with advanced and/or metastatic adenocarcinoma, performance status (PS) 0–2, and adequate
organ function who had previously been treated with standard chemotherapy were randomly assigned to receive
routine chemotherapy regimens with AC (20 ml twice daily) orally for 30 days or placebo. The primary endpoint
was 6-month overall survival (OS); the secondary endpoints were disease control rate (DCR), quality of life (QoL),
adverse event (AE), and biochemical features within 30 days of treatment.
Results: From August 2010 to July 2012, 37 subjects with gastric, lung, liver, breast, and colorectal cancer (17 in the
AC group, 20 in the placebo group) were enrolled in the study. Disease progression was the primary cause of death
in 4 (33.3 %) AC and 8 (66.7 %) placebo recipients. Mean OSs were 5.4 months for the AC group and 5.0 months for
the placebo group (p = 0.340), and the DCRs were 41.2 and 55 %, respectively (p = 0.33). Most hematologic, liver, or
kidney functions did not differ significantly between the two groups, but platelet counts were lower in the AC
group than in the placebo group (p = 0.02). QoL assessments were similar in the two groups, except that the AC
group showed significant improvements in quality of sleep (p = 0.04).
Conclusions: Although we found a lower mortality rate and longer mean OS in the AC group than in the control
group, A. cinnamomea combined with chemotherapy was not shown to improve the outcome of advanced cancer
patients, possibly due to the small sample size. In fact, the combination may present a potential risk of lowered
platelet counts. Adequately powered clinical trials will be necessary to address this question.
Trial registration: ClinicalTrials.gov NCT01287286.
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Background
Cancer is a serious health problem in Asia, and it is now
the leading cause of death in Asian Pacific countries
such as China, Japan, Korea, and Taiwan. The most
commonly diagnosed cancers in Eastern Asia, in de-
scending order, are lung, breast, colon, and rectum, and
the leading causes of cancer deaths are lung, stomach, and
liver cancer [1]. Garcia et al. reported that in the year
2007, an estimated 3.3 million people were diagnosed with
cancer and 2.3 million people died from cancer in Eastern
Asia. Their report also predicted that by 2020, an esti-
mated 7.1 million new cases of cancer will be diagnosed
each year if existing prevention and management strat-
egies remain unchanged [2].
The major conventional therapies for cancer are surgery,
chemotherapy, and radiotherapy. However, these therapies
have numerous limitations: (1) Most cancer patients are
diagnosed too late to undergo surgery, despite advances in
biomarker and radiographic research; (2) although chemo-
therapy and radiotherapy are effective against cancer, they
also have serious side effects and complications (e.g., fa-
tigue, pain, diarrhea, nausea, vomiting, and skin reactions);
(3) most advanced cancers have a survival rate of less than
5 years, and recurrence or metastasis is quite common
even after surgical resection; and (4) since some cancers
are relatively chemo- or radio-resistant, systemic cytotoxic
chemotherapy and radiotherapy are minimally effective at
improving patient survival [3, 4]. For these reasons, and in
spite of the uncertainty of its benefits due the lack of well-
controlled scientific studies, cancer patients have increas-
ingly turned to complementary and alternative medicine
(CAM) for treatment [5]. A recent study showed that in
Taiwan, up to 50.4 % of adults and 84.6 % of females use
some form of CAM to treat cancer [6].
Antrodia cinnamomea (AC), a well-known medical
mushroom used in Taiwan, has several pharmacological
functions, including antioxidant, anti-itching and hepa-
toprotective effects, as demonstrated by experimental
studies [7, 8]. AC extract contains a complex mixture of
bioactive ingredients, including triterpenoids, steroids,
polysaccharides, and phenyl and biphenyl compounds
[9]. It has recently become popular as a potential com-
plementary and alternative therapeutic agent for the
treatment of various cancers [10]. Previous studies re-
vealed that maleimide derivative isolated from AC atten-
uates the migration and invasion of breast cancer cells
[11]. Investigations by Hsu et al. have shown that AC
fruiting body extract exhibits a significant cytotoxic ef-
fect against hepatoma cell line Hep G2 and PLC/PRF/5
cells [12]. Furthermore, AC extract has adjuvant antipro-
liferative effects on hepatoma cells in vitro and in vivo
when combined with anti-tumor agents through the in-
hibition of Multi-Drug Resistance (MDR) gene expres-
sions and the pathway of COX-2-dependent inhibition
of phospho-AKT (p-AKT) [13]. However, the clinical ef-
fects of AC on cancer have not yet been demonstrated
in human trials. To increase understanding of the effects
of A. cinnamomea on cancer patients, we designed the
preliminary study and worked with oncologists and a
manufacturer to settle some of the controversy sur-
rounding AC treatment. In addition, we also evaluated
the safety and the alleviation of symptoms as a result of
treatment with AC in combination with chemotherapy
for patients in advanced stages.
Methods
Study design and patient selection
This prospective randomized, double-blind study was
undertaken in the Medical Oncology Department of
Kaohsiung Chang Gung Medical Hospital (KCGMH)
between August 2010 and July 2012. The protocol was
approved by the KCGMH Ethics Committee (IRB-98-
3904A3) and registered at clinicaltrials.gov under the
identification code NCT01287286. All participants pro-
vided written informed consent to participate in the study.
Patients aged ≥18 years were eligible if they had advanced
or recurrent, untreated, stage III-IV adenocarcinomas
that were histologically or cytologically confirmed; had
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previously received standard chemotherapy regimens;
and had an Eastern Co-operative Oncology Group (ECOG)
performance status (PS) of 0–2. Patients were excluded if
they were pregnant or lactating; had used any other investi-
gational agent within the 28 days prior to registration; had
a severe current illness; had an abnormal blood cell count,
liver function test, or creatinine clearance; or had known
hypersensitivity to any formulas of AC in the market.
Treatment
Eligible patients were randomly assigned to either the
AC group or the placebo group. The participants were
given 20-ml oral formulations twice a day for 30 days.
The A. cinnamomea used in the study comprised mainly
2100 mg polysaccharides, 172 mg triterpenoids, and
2687.5 mg γ-aminobutyric acid, and its Taiwan Symbol of
National Quality (SNQ) approval number was A00851.
The aqueous extract from mycelium of AC displayed cyto-
toxic activity with an IC50 value > 400 μg/ml in murine
RAW 264.7 cells. In addition, the freeze-dried state of AC
mycelia was administered for 28 days and 90 days respect-
ively to evaluate the oral toxicity in Sprague-Dawley (SD)
rats [14, 15]. Both studies showed the no-observed-
adverse-effect-level (NOAEL) and are safe to use as dietary
supplements or nutraceuticals.
Strains of AC were provided by the Research and De-
velopment Center (New Bellus Enterprises Co., Ltd,
Tainan, Taiwan). Extracts were prepared as previously
described by Cheng et al [16]. Briefly, AC was first cul-
tured with Malt Extract Agar (MEA) I broth containing
1.5 % agar, 1.5 % malt extract, 2 % glucose, and 0.1 %
peptone at 30 °C for 7–10 days. AC mycelia were inoc-
ulated into MEA I broth and incubated at 30 °C with
shaking for 8–10 days. After sterilization at 121 °C for
30 min, fermented extracts were centrifuged at 3000 g
for 10 min and then permeated through a 3000 MW
ultrafiltration membrane. The placebo was made of
malt, sucrose, and xanthan gum to achieve comparable
color, outlook, and taste to the AC. Both the AC and
placebo solutions were produced by Amon Biotech Co.,
Ltd (Lot no. AC9905245TA, Expiry Date/ EXP.: June
2010/ June 2013). Quality control was ensured. The AC
and placebo solutions were packed in sealed opaque
aluminum packages; only the treatment codes and
administration instructions were printed on the out-
sides of the package to ensure successful blinding of
the patients.
Eligible patients with lung cancer were scheduled to
receive platinum-based chemotherapy with cisplatin
dosed at 60 − 75 mg/m2 or a carboplatin area under the
curve (AUC5). The following regimens were sequentially
adopted for this study at the discretion of the investigator
in accordance with the National Comprehensive Cancer
Network (NCCN) guidelines for patients with breast,
stomach, liver, and colorectal cancers: adriamycin-based,
taxane- or vinorelbine-based, 5-fluorouracil (5-FU)-based
and oxaliplatin-based chemotherapy (Table 1) [17]. After
the first dose of standard chemotherapy, the patients
began treatment with a 30-day supply of the agent and
were asked to return the containers at the next scheduled
visit (on days 7, 15, and 30). Counting the unused boxes
served as a measure for compliance with treatment. Pa-
tients were withdrawn from the trial if they failed to ap-
pear for the next two scheduled visits or if they had not
used at least 80 % of the supplied treatment at 75 % of the
treatment intervals.
Efficacy and safety assessment
The primary endpoint of this analysis was overall survival
(OS). OS was calculated from the date of randomization
until the date of death or the last 6-month follow-up. The
secondary endpoints were the disease control rate (DCR)
(complete response (CR), partial response (PR), and stable
disease (SD)), as determined by Response Evaluation Cri-
teria in Solid Tumors (RECIST) version 1.1. Tumor assess-
ments using computed tomography scans were performed
before A. cinnamomea treatment and 30 days thereafter.
Other secondary outcome measures included Quality of life
(QoL), adverse event (AE), and clinical and laboratory
assessments conducted at baseline and at 30 days after
administration. QoL was measured using the European
Organization for Research and Treatment-Quality of Life
Questionnaire (EORTC-QLQ-C30) and the Multidimen-
sional Fatigue Inventory (MFI-20). The incidence and se-
verity of AEs were graded according to the National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0.
Table 1 Chemotherapeutic protocols for different advanced cancer types according to NCCN guidelines and their adverse events
Cancer type Chemotherapeutic regimens Common adverse events
Lung Platinum-based Nausea, vomiting, nephrotoxicity, bone marrow suppression
Breast Adriamycin-based or taxane-based Bone marrow suppression, nausea, vomiting, alopecia
Stomach Oxaliplatin/5-fluouracil Nausea, vomiting, mucositis, diarrhea, bone marrow suppression
Liver Adriamycin and Cisplatin Nausea, vomiting, bone marrow suppression, nephrotoxicity
Colorectal Oxaliplatin-based or Irinotecan-based Nausea, vomiting, diarrhea, bone marrow suppression
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Statistical analyses
The baseline characteristics and clinical data of the pa-
tients treated with chemotherapy plus AC or placebo are
presented as number and mean ± standard deviation
(SD). Overall survival (OS) for both groups was mea-
sured from randomization until death from any cause.
Patients that were alive but lost to follow-up were ex-
cluded at the last follow-up date. OS was illustrated by
means of Kaplan-Meier curves, and log-rank tests were
used to compare survival between the two groups. The
Chi-square test was used to compare the treatment re-
sponse in the two groups, separated as DCR vs. progres-
sive disease (PD). The data on the QoL, clinical, and
laboratory assessments for the pre- and post-tests within
the AC group and the placebo group were assessed by
Wilcoxon signed-rank test. Differences in efficacy between
the two groups were determined by Mann-Whitney U-
test. All statistical analyses were performed with SPSS
version 18 for Windows. A p value < 0.05 was consid-
ered statistically significant.
Result
Between August 2010 and July 2012, a total of 37 pa-
tients were recruited into the study and considered for
the full analysis (Fig. 1). Of the 37, 17 received chemother-
apy with A. cinnamomea, and 20, chemotherapy with pla-
cebo. Patient demographics and disease characteristics are
presented in Table 2.
At the 30-day analysis, patients had experienced 2.35
and 1.75 chemotherapy cycles schedule while on AC and
placebo treatment, respectively. Four cases of disease
progression (23.5 %) had occurred in the AC group and
4 (20 %) in the placebo group, and no deaths or with-
drawals were recorded. By the cut-off date at 6 months
of treatment, a total of 12 patients had died (32.4 %), 25
patients were surviving (67.6 %), and 4 patients in the
placebo group were lost to follow-up. Disease progres-
sion was the primary cause of death in 4 (33.3 %) AC
and 8 (66.7 %) placebo recipients. There was no statisti-
cally significant difference in survival between the treat-
ment groups; mean OSs were 5.4 months (AC group)
and 5.0 months (placebo group; p = 0.340; Fig. 2). As
shown in Table 3, 29 of the 37 patients (13 patients in
the AC group and 16 patients in the placebo group)
had measurable lesions and could be evaluated for re-
sponse based on the RECIST criteria. No complete re-
sponse was observed in either treatment group. Three
patients in the AC group achieved PR, four patients
were SD, and the remaining six patients were PD. In
the placebo group, three patients achieved PR, eight pa-
tients were SD, and the remaining five patients were
PD. The DCRs were 41.2 and 55 % in the AC and pla-
cebo groups, respectively. There were no significant
differences in the objective DCR vs. PD in the two
groups (p = 0.33).
All patients completed the two quality of life forms
(Table 4). Most of the EORTC-QLQ-C30 assessments
did not show significant differences between the treatment
groups with regard to the mean scores from baseline to
30 days, but quality of sleep improved significantly more
in the AC group than in the placebo group (p = 0.04).
There was no difference in fatigue levels on the general
subscale of the MFI-20 between the two groups.
All laboratory parameters were comparable in the AC
group and the placebo group as compared with baseline,
and similar trends between both groups were observed
throughout the study period (Table 5). After 30 days of
treatment, the AC group showed a significant decrease
in platelet count (p < 0.01). We also detected a signifi-
cant difference in the decreases in the platelet counts in
Fig. 1 Flow chart
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the two groups (p = 0.02). Other tested biomarkers did
not demonstrate significant changes in the two groups.
Various treatment-related adverse events (any grade)
due to the chemotherapy plus either A. cinnamomea or
placebo in this study are reported in Table 6. Gastrointes-
tinal complaints were the most common AEs reported
during the study. Most of the gastrointestinal complaints
were of grade 1–2 in the AC group. Additionally, one
patient receiving placebo reported grade 3 diarrhea (in-
creasing to ≥7 stools per day). Four patients suffered
severe abdominal pain in the placebo group due to
disease progression. The grade 3–4 AEs in other pa-
tients in both groups were related to disease progres-
sion, except that an 81 y/o patient with gastric cancer
in the AC group developed upper gastrointestinal (GI)
bleeding after 10 doses of AC.
Discussion
This double-blind randomized clinical trial examined the
impact of 30-day A. cinnamomea treatment on the effi-
cacy and safety associated with chemotherapy in patients
with advanced cancers. Despite the strong scientific ra-
tionale in the biotechnology industry [12, 18, 19], the
combination of AC and standard chemotherapy regi-
mens failed to improve the survival and response rates
of the AC group relative to those of the placebo group
in patients with advanced cancers.
A recent preclinical study demonstrated the antitumor
effect of AC on non-small cell lung cancer cells both
in vitro and in vivo with bioluminescence imaging and
indicated that the inhibition of tumor proliferation may
be related to induced apoptosis [20]. Moreover, AC has
been shown to enhance the cytotoxic effect of chemo-
therapy on ovarian cancer and hepatoma cells [13, 21].
Table 2 Baseline characteristics of patients treated with
chemotherapy plus A. cinnamomea (AC) or placebo
Chemotherapy +
AC (n = 17)
Chemotherapy +
placebo (n = 20)
Sex (male/female) 10/7 8/12
Age (Mean ± SD) 56.71 ± 9.61 53.10 ± 10.86
Body weight in kg (Mean ± SD) 61.98 ± 9.09 60.36 ± 11.11
Months of prior treatment
(Mean ± SD)
9.80 ± 3.46 8.55 ± 4.03
Tumor location (TNM stage, AJCC, 2002)
Lung (stage IV) 1 7
Breast (stage IV) 4 4
Stomach (stage III-IV) 5 5
Liver (stage III-IV) 3 1
Colorectal (stage IV) 4 3
Fig. 2 Kaplan-Meier curves of 6-month survival for chemotherapy plus A. cinnamomea (AC) or placebo
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These results have led to AC being used widely in certain
populations and kept its price high in Taiwan. However,
the sweet success of herbal or folk medicine agents in ani-
mal studies and the bitter aftertaste in clinical studies have
recently been a major topic of discussion in research [22].
Known experimental factors, including the animal model,
target selection, recommended dose, and differences in co-
morbidities, influence all treatments from cellular therapy
to new drug application [23]. Despite the nonexistence of
a clear anti-cancer effect found in this trial, given the ana-
lyses of OS and DCR of AC treatment, a potential finding
is that AC does not affect the progression of cancer when
combined with chemotherapy.
Advanced or metastatic cancer is predictably associated
with challenges and burdens that may lead to symptoms
of fatigue, toxicities of cancer therapy, and compromised
patient QoL and mortality [24, 25]. The production of re-
active oxygen species (ROS) is an important contributor
to these symptoms and metabolic abnormalities [26]. Al-
though AC is used for protection against oxidative damage
and elimination of fatigue [27, 28], this study did not find
a significant benefit on fatigue or QoL-related outcomes
in patients treated with AC. Only for quality of sleep was
AC more effective than the placebo. It is known that sleep
disturbances affect 30–50 % of cancer patients and con-
tribute additional risks of depression, fatigue, heightened
pain, and decrement of survival rates [29, 30]. Evidence is
growing that disruptions in biological rhythmicity are also
relevant to cancer. The mitotic properties of cancerous
cells themselves, the treatments of cancer, the time of day
of treatment administration, and possibly the quality of life
of cancer patients all affect outcomes [31]. A recent study
reported that poor sleep quality may be associated with in-
creases in oxidative stress indicators and decreases in free
radical scavenging anti-oxidants [32]. However, few studies
to date have investigated the relationship between AC and
the improvement of quality of sleep. This finding in our
study, that AC may improve the quality of sleep, is
worthy of further exploration, but the evidence does
not support a strong recommendation. Further research is
needed in order to examine the potential impacts of the
integrative model of care on specific outcomes, such as
Table 3 Best overall response and disease control rate per
RECIST (Full Analysis Population)
Chemotherapy +
AC (n = 17)
Chemotherapy +
placebo (n = 20)
p-value
Best overall response, No. (%)a
Complete response (CR) 0 0
Partial response (PR) 3 (17.6) 3 (15)
Stable disease (SD) 4 (23.5) 8 (40)
Progressive disease (PD) 6 (35.3) 5 (25)
Unknown 4 (23.5) 4 (20)
Disease control rate
(CR + PR + SD)
7 (41.2) 11 (55) 0.33
aProportion of patients whose best overall response is complete response,
partial response, or stable disease according to RECIST (Response Evaluation
Criteria in Solid Tumors)
Table 4 Quality of life of cancer patients treated with chemotherapy plus A. cinnamomea (AC) or placebo
Chemotherapy + AC (n = 17) p-valuea Chemotherapy + placebo (n = 20) p-valuea p-valueb
Pre-test Post-test Pre-test Post-test
EORTCQLQ-C30
General condition 49.51 ± 11.20 55.55 ± 28.63 0.08 53.75 ± 26.27 53.07 ± 23.10 0.28 0.76
Fatigue 26.79 ± 27.23 34.72 ± 36.03 0.18 28.33 ± 18.19 41.52 ± 28.16 0.06 0.32
Nausea and vomiting 22.54 ± 34.32 10 ± 18.68 0.08 9.16 ± 18.31 16.66 ± 26.64 0.24 0.51
Pain 14.70 ± 21.95 25.55 ± 30.12 0.04 19.16 ± 23.74 21.92 ± 28.89 0.38 0.77
Shortness of breath 9.80 ± 19.59 11.11 ± 20.57 0.31 13.33 ± 19.94 19.29 ± 25.61 0.15 0.30
Sleep disturbance 47.05 ± 42.58 40.00 ± 36.07 0.37 46.66 ± 38.08 61.40 ± 35.59 0.01 0.04
Lack of appetite 27.45 ± 35.81 22.22 ± 29.99 0.44 18.33 ± 27.51 31.57 ± 34.19 0.03 0.44
Constipation 15.68 ± 20.80 17.77 ± 27.79 0.28 21.66 ± 31.11 8.77 ± 18.73 0.02 0.29
Diarrhea 5.88 ± 13.09 6.66 ± 13.80 0.12 1.66 ± 7.45 10.52 ± 24.97 0.21 0.86
MFI - 20
General Fatigue 10.41 ± 1.50 10.6 ± 2.26 0.35 10.55 ± 1.84 10.15 ± 2.03 0.21 0.41
Physical Fatigue 12.23 ± 0.90 12.13 ± 1.41 0.33 11.95 ± 0.82 12.25 ± 1.11 0.24 0.78
Reduced Activity 11.23 ± 1.60 11.66 ± 0.90 0.47 11.20 ± 1.54 11.15 ± 1.26 0.43 0.12
Reduced Motivation 12.76 ± 1.82 13.00 ± 1.41 0.15 12.55 ± 1.23 12.50 ± 1.39 0.33 0.37
Mental Fatigue 11.17 ± 1.07 11.33 ± 1.11 0.20 10.9 ± 1.77 11.95 ± 1.35 0.01 0.28
aWilcoxon signed-rank test (Within group)
bMann-Whitney U test (Differences in efficacy between two groups)
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chemotherapy-induced and cancer-related fatigue, as well
as other QoL-related concerns.
In the minds of many patients, A. cinnamomea is a
natural component with high antioxidant and polysac-
charide contents. The lack of toxicity reported in previ-
ous studies might indicate that is safe for use as a
functional food ingredient [33, 34]. However, the adverse
events observed in patients treated with AC in our study
were generally consistent with its known adverse event
profile. A study published in China concluded that the
property and flavor of AC are cold and bitter [35]. Ac-
cording to Traditional Chinese Medicine (TCM) theory,
the barrier function of gastric mucosa is inhibited after
the intake of an excessive amount of bitter and cold
medicine, possibly leading to damage to the stomach
[36]. If these medicines are taken for an extended period
or in large doses, the decreases in prostaglandin E2 and
increases in products of lipid peroxidation in gastric mu-
cosa will produce oxidative stress and its companions,
such as inflammation. Our findings showed AC to cause
mild to moderate irritation in the GI tract at intake,
especially in debilitated patients. The incidence of GI
reactions, including abdominal pain and diarrhea, was
much greater in the AC group (47.1 %) than in the pla-
cebo group. In clinical practice, the AC-associated GI
reactions can be alleviated by keeping pieces of ginger
(Zingiber officinale Roscoe) in the mouth after AC in-
take, for this warm and acrid medicine can restrain the
cold and bitterness, according to the TCM compatibility
of herbal medicines [37]. Recent studies have demon-
strated that ginger may provide a protective effect against
drug-induced gastric injury and have a potential ulcer-
preventive ability [38, 39]. However, because the precise
mechanism of the interaction of AC and ginger has yet to
be elucidated, we cannot exclude the possibility that an
antagonistic effect of the combined agents may play
some role.
The majorities of enrolled patients in both groups had
advanced adenocarcinoma and were receiving similar
chemotherapy regimens. The laboratory parameters
regarding hematological and non-hematological safety
were comparable in both treatment groups. There was
Table 5 Body weight, hematological and non-hematological data follow-up for patients taking chemotherapy plus A. cinnamomea
(AC) or placebo
Chemotherapy + AC (n = 17) p-valuea Chemotherapy + placebo (n = 20) p-valuea p-valueb
Pre-test Post-test Pre-test Post-test
Hematological
WBC (103/ul) 6.1 ± 2.64 11.55 ± 1.30 0.38 5.75 ± 3.23 11.47 ± 1.48 0.34 0.10
Hemoglobin (g/dl) 11.57 ± 1.17 6.17 ± 2.77 0.43 11.75 ± 2.03 5.69 ± 2.16 0.77 0.79
Platelet (103/ul) 179.11 ± 65.11 141.71 ± 63.47 <.001 201 ± 68.97 196.55 ± 74.47 0.33 0.02
Non-hematological
Bilirubin (mg/dl) 0.64 ± 0.17 0.79 ± 0.78 0.48 0.49 ± 0.19 0.62 ± 0.28 0.12 0.62
AST (u/l) 37.88 ± 22.01 39.62 ± 26.38 0.33 27.75 ± 11.68 26.50 ± 9.73 0.30 0.07
ALT (u/l) 29.70 ± 17.50 28.70 ± 15.46 0.14 20.33 ± 10.28 29.89 ± 9.46 0.42 0.09
Creatinine (mg/dl) 0.82 ± 0.29 0.86 ± 0.30 0.11 0.72 ± .17 0.78 ± 0.17 0.10 0.73
Body weight (kg) 61.98 ± 9.09 61.24 ± 9.13 0.21 60.36 ± 11.11 59.45 ± 11.36 0.13 0.53
aWilcoxon signed-rank test (Within group)
bMann-Whitney U test (Differences in efficacy between two groups
Table 6 Common adverse events (AEs) of 37 cancer patients treated with chemotherapy plus either A. cinnamomea or placebo
Chemotherapy + AC (n = 17) Chemotherapy + placebo (n = 20)
Grade 1–2, N (%) Grade 3–4, N (%) Grade 1–2, N (%) Grade 3–4, N (%)
Abdominal pain 5 (29.4) 1 (5) 4 (20)
Diarrhea 3 (17.6) 1 (5)
Dry mouth 1 (5.9)
Blurred vision 1 (5)
Dyspnea 2 (11.8)
Intracranial hemorrhage 1 (5.9)
Upper gastrointestinal bleeding 1 (5.9) 1 (5)
Infection 1 (5.9) 2 (10)
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a significant decrease in platelet counts within 30 days
of adjuvant AC treatment. Our data also indicated a
large difference in the decline in platelet levels between
the two groups in patients with lung cancer (83.5 % vs.
−5.0 %) and gastric cancer (22.4 % vs. −4.9 %). However,
the relationship between the decrease in platelet counts
and adjuvant AC treatment was not well established in
our study.
Thrombocytopenia in itself is sometimes just a paper
laboratory value, and the toxicity does not affect pa-
tient safety or outcome. However, a platelet count
below 10 × 109/L (and maybe < 5 × 109/L) often leads
to an increased risk of bleeding in cancer patients and
can accelerate morbidity [40, 41]. Patients exposed to
chemotherapeutic agents, such as cyclophosphamide
(CTX), methotrexate (MTX), 5-FU, cytarabine (Ara-C),
and etoposide (VP-16), are at higher risk of experiencing
thrombocytopenia due to their effects on the production
of blood cell progenitors [42]. In our study, few pa-
tients received the above chemotherapeutic agents, ex-
cept 5-FU for liver or colorectal cancer. The extent of
thrombocytopenia was analyzed in both groups, and
patients with liver or colorectal cancer exhibited no sig-
nificant differences from the others. Though this observa-
tion spanned only a short period, the finding may imply
an association between AC and its platelet-lowering effect
in patients with lung or gastric cancer. Most research has
focused on the antiplatelet activity of AC as a potential
therapeutic agent for treating thromboembolic disorders
[43, 44]. However, no definitive proof demonstrates that
AC interferes with the processes of platelet production,
destruction, and pooling. We are fully aware that our sam-
ple size was limited and that the data analysis in our study
had its restrictions. However, the harmful effect of AC in
the treatment of cancer is unknown to the public, espe-
cially in the case of advanced cancer patients, so the find-
ings of this study could provide some preliminary data.
The small sample size and the recruitment of patients
with different types of cancer are the most important
problem of our study. For this reason, the study may
have had insufficient power to detect significant differences
for anti-cancer effects. We know every cancer has its own
characteristics and natural course, but it is important to
manage the cancer-related symptoms and adverse events
of chemotherapy, especially in the advanced stage. Al-
though disappointing results could be anticipated for can-
cer patients in advanced stage even with the use of plant
extract. We still can observe some phenomena, including
safety and physical symptoms, after AC treatment. The re-
sults should be informative for health care professionals
and our patients.
This clinical study had several limitations. First, this
plant extract has multiple potent mechanisms and differ-
ent activity, but this study was assayed only some test
and, in fact is a marginal experiments. Second, the treat-
ment lasted only 30 days, so related changes in prognos-
tic indicators could not be demonstrated. Longer or
continued AC treatment may be required for clinically
significant changes in patient well-being to be observed.
Third, due to the restrictions on sample collection from
advanced cancer patients, the study neither evaluated
the relationship between a target cancer and AC usage
nor elucidated the effects of AC treatment. Finally, AC is
not yet regulated by the Food and Drug Administration.
Some studies previously also reported that different ex-
tracts from A. camphorata showed cytotoxic activity, so
it is need to determine cytotoxic dose and IC50 value
before being a complementary therapy [45]. Further in-
vestigation using a more sample, distinct cancer in early
stage, long-term treatment, and rigorous design will be
needed to determine the efficacy of A. cinnamomea.
Conclusions
A. cinnamomea is a popular folk medicine and has
attracted great attention due to its reputation for anti-
cancer activity against several types of cancer, but little
information is available on its clinical application. This
study is the first to report the therapeutic effects of this
medical fungus in advanced cancer patients receiving
standard chemotherapy. The mean 6-month survival rate
was not significantly different between groups (5.4 months
vs. 5 months, AC versus placebo, respectively). The only
significant difference between groups was the platelet
counts, which were lower in the AC group, and sleep qual-
ity, which was significantly improved in the AC group.
Overall, AC combined with chemotherapy did not improve
the outcomes in the advanced cancer patients.
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